KEY POINTS
- This consensus paper emerged from the ESTRO Physics Workshop on spatially fractionated radiation therapy (SFRT) held in Toulouse, France, on 23–24 October 2025. The workshop included 28 delegates from 14 countries, comprising 22 medical physicists, two radiobiologists, two equipment-vendor scientists, one radiation oncologist, and one radiation therapist. Recommendations were developed through structured presentations, breakout discussions, and plenary agreement rather than formal Delphi voting or systematic evidence grading.
- The workshop focused primarily on photon and proton GRID and Lattice radiotherapy, increasingly used for bulky, unresectable, radioresistant, or recurrent malignancies. Reported institutional practices vary substantially: typical GRID aperture diameters range from 1.0–2.0 cm, with 2.0–3.0 cm center-to-center spacing, while Lattice vertex diameters range from 1.0–2.0 cm, with spacing of approximately 3.0–6.0 cm. These variations complicate comparisons of treatment plans and clinical outcomes because SFRT intentionally creates highly heterogeneous dose distributions.
- Five major barriers to standardized SFRT implementation were identified: inconsistent dose recording and reporting, variable commissioning and patient-specific QA practices, insufficient motion-management and robustness criteria, fragmented multicenter clinical data collection, and lack of coordinated international governance. Unlike conventional RT, SFRT cannot be adequately characterized by target coverage and conventional homogeneity indices alone, since the geometry and magnitude of high-dose peaks and low-dose valleys are central to its intended biological effect.
- The proposed reporting framework emphasizes both spatial geometry and dose heterogeneity. Recommended parameters include peak dose, valley dose, peak-to-valley dose ratio (PVDR), volume dose ratio (VDR), mean GTV dose, vertex size, spacing, number, distribution, and prescription methodology. Because point-based maximum and minimum doses can be highly sensitive to calculation resolution, the authors recommend supplementing PVDR with more robust volumetric indices, such as GTV D5%/D95% or D10%/D90%, and comparing mean vertex dose with mean valley-region dose. These definitions are explicitly provisional and require further international validation.
- Commissioning and patient-specific QA should address the spatial dose pattern rather than relying exclusively on conventional gamma passing rates. The workshop recommended high-resolution small-field dosimetry, appropriate detector selection, and end-to-end verification of peak and valley dose distributions. Candidate methods include radiochromic films, high-resolution detector arrays, three-dimensional gel or scintillator dosimetry, ion-chamber measurements at defined peak and valley locations, and independent Monte Carlo calculations. Existing SFRT QA studies use criteria ranging from 3%/3 mm to 2%/2 mm, but no universally validated SFRT-specific acceptance threshold currently exists.
- Motion management was identified as a major unresolved safety concern. Respiratory motion, setup variation, tumor shrinkage, and organ deformation can displace high-dose vertices and alter the intended peak-to-valley relationships, particularly in proton-based SFRT. The authors recommend explicit documentation of 4D-CT assessment, gating or tracking criteria, geometric robustness evaluation, intrafraction motion thresholds, and repeat imaging. Commonly used gating windows of approximately ±3 mm have not been validated as sufficient for maintaining SFRT spatial dose geometry, and no universal SFRT-specific motion tolerance was proposed.
- A three-phase implementation roadmap was proposed. During years 0–2, priorities include provisional reporting definitions, minimum commissioning and QA specifications, common registry data elements, and formation of an international working group. During years 2–5, the proposed milestones include multicenter phantom benchmarking, incorporation of SFRT criteria into at least one prospective trial credentialing program, and registry participation from at least 10 institutions. Beyond five years, accumulated clinical evidence should inform finalized guidance and ongoing benchmarking. These are future objectives, not achievements already implemented or formally adopted by ESTRO.
CLINICAL TAKEAWAY
The ESTRO workshop roadmap provides a structured starting point for harmonizing spatially fractionated radiotherapy across institutions, particularly in dose reporting, QA, motion management, and prospective study design. However, the recommendations remain workshop-based expert consensus rather than validated clinical standards, and future development will require broader clinical representation and multicenter evidence before specific implementation thresholds can be considered established.